Biochemical recurrence is a clinical situation experienced by 20 to 40% of prostate cancer patients treated with radical prostatectomy (RP).Prostate bed Gastro-Intestinal Tract Support (PB) radiation therapy (RT) remains the mainstay salvage treatment, although it remains non-curative for up to 30% of patients developing further recurrence.Positron emission tomography with computed tomography (PET/CT) using prostate cancer-targeting radiotracers has emerged in the last decade as a new-generation imaging technique characterized by a better restaging accuracy compared to conventional imaging.By adapting targeting of recurrence sites and modulating treatment management, implementation in clinical practice of restaging PET/CT is challenging the established therapeutic standards born from randomized controlled trials.
This article reviews the potential impact of restaging PET/CT on changes in the management of recurrent prostate cancer after RP.Based on MEN 50+ MULTIVITAMINS PET/CT findings, it addresses potential adaptation of RT target volumes and doses, as well as use of androgen-deprivation therapy (ADT).However, the impact of such management changes on the oncological outcomes of PET/CT-based salvage RT strategies is as yet unknown.